Brief: Emergent BioSolutions Q4 Revenue USD 148.7 Million

Emergent BioSolutions

26/02/2026 21:05

Feb 26 (Reuters) - Emergent BioSolutions Q4 adjusted net income USD -22.7 million.

Q4 net income USD -54.6 million

Q4 adjusted EBITDA USD 11.2 million

Q4 adjusted EPS USD -0.43

Q4 adjusted gross margin 43%

Q4 gross margin 30%

outlook FY net income USD -30 to -10 million

outlook FY adjusted net income USD 25-45 million